Investors in Simulations Plus witnessed a significant rebound in the stock’s value last week, with shares climbing over 21% through Thursday. This surge was primarily fueled by management’s reaffirmation of its fiscal 2026 outlook, an action interpreted as a sign of underlying stability despite a mixed performance in the company’s final quarter.
The provider of simulation and modeling software for pharmacology reported total revenue of $79.2 million for fiscal 2025, marking a 13% year-over-year increase. Its adjusted earnings per share came in at $1.03. However, the fourth quarter presented a softer picture: revenue declined 6% to $17.5 million, with software revenue specifically falling 9%. Furthermore, a substantial non-cash impairment charge of $77.2 million resulted in a GAAP net loss of $64.7 million for the full year.
Confidence in Forward Guidance Drives Momentum
The market’s positive reaction centered squarely on the confirmed projections for the ongoing 2026 fiscal period. Company leadership expects revenue to land between $79 million and $82 million, with adjusted EPS forecasted in the range of $1.03 to $1.10. This guidance, suggesting continued growth amid challenging conditions, was received by the investment community as a credible vote of confidence in the firm’s trajectory. Based on the 2026 forecast, the shares now trade at a forward price-to-earnings multiple below 20.
Should investors sell immediately? Or is it worth buying Simulations Plus?
Historical Highs Remain a Distant Target
Even with the recent advance, the equity remains far below its peak valuations.
* It currently trades 44% below its 52-week high.
* The share price is approximately 77% removed from its all-time high.
A potential catalyst for a more durable recovery may arrive in January with the scheduled unveiling of a revised product strategy. The company has indicated it will place a significant emphasis on artificial intelligence-powered solutions. The forthcoming quarterly results, expected on January 6, 2026, will provide the first concrete evidence on whether this strategic shift is beginning to yield results.
Ad
Simulations Plus Stock: Buy or Sell?! New Simulations Plus Analysis from December 6 delivers the answer:
The latest Simulations Plus figures speak for themselves: Urgent action needed for Simulations Plus investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 6.
Simulations Plus: Buy or sell? Read more here...
